Vaccination against COVID-19 in patients with allergy: experience of the allergological center in Dnipro

Authors

  • Ye.M. Dytiatkovska Dnipro state medical university, Volodymyra Vernadskoho str., 9; Municipal Non-Profit Enterprise «Clinical Hospital of Emergency Medical Care» DCC, Volodymyra Antonovycha str, 65, Dnipro, 49044, Ukraine https://orcid.org/0000-0001-9007-8634
  • K.Yu. Gashynova Dnipro state medical university, Volodymyra Vernadskoho str., 9; Municipal Non-Profit Enterprise «Clinical Hospital of Emergency Medical Care» DCC, Volodymyra Antonovycha str, 65, Dnipro, 49044, Ukraine https://orcid.org/0000-0003-2955-9687
  • Ye.V. Korietskaia Dnipro state medical university, Volodymyra Vernadskoho str., 9; Municipal Non-Profit Enterprise «Clinical Hospital of Emergency Medical Care» DCC, Volodymyra Antonovycha str, 65, Dnipro, 49044, Ukraine https://orcid.org/0000-0003-3891-8813
  • M.A. Yevtushenko Municipal Non-Profit Enterprise «Clinical Hospital of Emergency Medical Care» DCC, Volodymyra Antonovycha str, 65, Dnipro, 49006, Ukraine https://orcid.org/0000-0002-8088-5608

DOI:

https://doi.org/10.26641/2307-0404.2023.2.283163

Keywords:

COVID-19, vaccination, anaphylaxis, hypersensitivity, anphylactogenic substances, tryptase, immunoglobulin E, bronchial asthma, urticaria, allergic rhinitis, hay fever, mastocytosis, atopic dermatitis, comorbidity

Abstract

Vaccination against COVID-19 is the main global preventive measure in the fight against SARS-CoV-2. As the COVID-19 vaccine will be administered to billions of individuals worldwide during the pandemic, there exists a reasonable fear of severe adverse reactions requiring constant vigilance and careful treatment, particularly in individuals with a history of severe allergy. The aim of our study was to develop and implement an algorithm for the safe vaccination against COVID-19 in patients with pathology associated with hypersensitivity reactions. From January to June 2022, after signing the informed consent, 126 adult patients with relevant diseases in remission were included in a prospective single-center study. Complaints and case histories were collected from all patients, including comorbidity and medications received, anthropometric data were studied, a standard clinical examination was performed, tryptase in venous blood was measured, the level of control was additionally assessed in patients with asthma using the asthma control test and spirography. According to the results of the study, it was proven that vaccination against COVID-19 in patients with pathology associated with hypersensitivity reactions is safe, on condition of prior consultation with an allergist and performing vaccination in a medical institution. The algorithm developed for preparing for vaccination in the mentioned above persons consists of a careful collection of case history; assessment and, in case of absence – achieving control of the underlying disease; analysis and correction of therapy with temporary replacement of medications that are potential cofactors of anaphylaxis; determination of blood tryptase level. For safe vaccination in patients with severe allergic anamnesis, administration of 20 mg of desloratadine before each dose of the vaccine with observation after vaccination within 30 minutes is suggested.

References

Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, et al. Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper. Allergy. 2022 Aug;77(8):2292-312. doi: https://doi.org/10.1111/all.15241

Bousquet J, Agache I, Blain H, Jutel M, Ventura MT, Worm M, et al. Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021 Oct;76(10):2952-64. doi: https://doi.org/10.1111/all.14838

Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID‐19 disease and reported allergic reactions: current evidence and approach. J Allergy Clin Immunol Pract. 2021;9(4):1423-37. doi: https://doi.org/10.1016/j.jaip.2020.12.047

Klimek L, Jutel M, Akdis CA, et al. ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines – an EAACI‐ARIA position paper. Allergy. 2021;76(6):1624‐8. doi: https://doi.org/10.1111/all.14726

Shimabukuro T. COVID‐19 vaccine safety update. Advisory Committee on Immunization Practices (ACIP) January 27, 2021. National Center for Immunization and respiratory diseases CDC [Internet]. 2021 [cited 2022 Dec 10]. Available from: https://wwwcdcgov/vaccines/acip/meetings/downloads/slides‐2021‐01/06‐COVID‐Shimabukuropdf

Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer‐BioNTech COVID‐19 vaccine. JAMA 2021;325(8):780. doi: https://doi.org/10.1001/jama.2021.0600

Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of the mRNA‐1273 vaccine for COVID‐19: Possible involvement of polyethlene glycol and IgG‐mediated complement activation. Allergy. 2021 Nov;76(11):3307-13. doi: https://doi.org/10.22541/au.160952242.21038379/v1

Caminati M, Guarnieri G, Senna G. Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine? Vaccines. 2021;9:38. doi: https://doi.org/10.3390/vaccines9010038

Francuzik W, Dölle-Bierke S, Knop M, Scherer Hofmeier K, Cichocka-Jarosz E, García BE, et al. Refractory Anaphylaxis: Data From the European Anaphylaxis Registry. Front Immunol. 2019 Oct 18;10:2482. doi: https://doi.org/10.3389/fimmu.2019.02482

Cabanillas B, Akdis C, Novak N. Allergic reactions to the first COVID‐19 vaccine: a potential role of Polyethylene glycol? Allergy. 2021;76(6):1617‐8. doi: https://doi.org/10.1111/all.14711

Worm M, Ring J, Klimek L, Jakob T, Lange L, Treudler R, et al. Anaphylaxie-Risiko bei der COVID-19-Impfung: Empfehlungen für das praktische Management [Covid-19 vaccination and risk of anaphylaxis – Recommendations for practical management]. MMW Fortschr Med. 2021 Jan;163(1):48-51. doi: https://doi.org/10.1007/s15006-021-9530-6

Gashynova K, Suska K, Dmytrychenko V. Microbiome landscape and disease duration role in allergy in adult patients with bronchiectasis. Eur Respir J. 2019;54(63):PA2763. doi: https://doi.org/10.1183/13993003.congress-2019.PA2763

Dytyatkovska E, Gashynova K, Panov V. Patterns of molecular sensitization in adults in Dnipro region (Ukraine). Allergy. 2019;74:831-2. doi: https://doi.org/10.37219/2528-8253-2020-6-42

Perceva TA, Gashinova EYu. ["Difficult" asthma: life goes on]. Zdorovia Ukrainy. 2007;8:165. Russian.

[On the approval and implementation of medical and technological documents on the standardization of medical care for bronchial asthma. Order of the Ministry of Health of Ukraine dated October 8, 2013 No. 868]. [Internet]. 2013 [cited 2022 Aug 26]. Available from: https://zakon.rada.gov.ua/rada/show/v0868282-13#Text

Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983Jan.1;127(6):725-34.

Glantz SA. Primer of biostatistics. 4th ed. New York: McGraw-Hill, Health Professions Division; 1997. 473 p.

Ring J, Beyer K, Biedermann T, et al. Guideline (S2) on acute therapy and management of anaphylaxis: 2021 update. S2- Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Medical Association of German Allergologists (AeDA), the Society of Pediatric Allergy and Environmental Medicine (GPA), the German Academy of Allergology and Environmental Medicine (DAAU), the German Professional Association of Pediatricians (BVKJ), the Society for Neonatology Paediatric Intensive Care (GNPI), the German Society of Dermatology (DDG), the Austrian Society for Allergology and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Anaesthesiology and Intensive Care Medicine (DGAI), the German Society of Pharmacology (DGP), the German Respiratory Society (DGP), the patient organization German Allergy and Asthma Association (DAAB), the German Working Group of Anaphylaxis Training and Education (AGATE). Allergo J Int. 2021;30:1-25. doi: https://doi.org/10.1007/s40629-020-00158-y

Published

2023-06-30

How to Cite

1.
Dytiatkovska Y, Gashynova K, Korietskaia Y, Yevtushenko M. Vaccination against COVID-19 in patients with allergy: experience of the allergological center in Dnipro. Med. perspekt. [Internet]. 2023Jun.30 [cited 2024Jul.16];28(2):42-9. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/283163

Issue

Section

CLINICAL MEDICINE